SATRALIZUMAB-MWGE for Demyelination: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 15 adverse event reports in the FDA FAERS database where SATRALIZUMAB-MWGE was used for Demyelination.
Most Reported Side Effects for SATRALIZUMAB-MWGE
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Neuromyelitis optica spectrum disorder | 181 | 16.3% | 3 | 67 |
| Off label use | 87 | 7.8% | 2 | 37 |
| Urinary tract infection | 87 | 7.8% | 3 | 58 |
| Pneumonia | 64 | 5.8% | 4 | 54 |
| Covid-19 | 47 | 4.2% | 5 | 25 |
| No adverse event | 47 | 4.2% | 0 | 0 |
| Fatigue | 41 | 3.7% | 0 | 10 |
| Headache | 36 | 3.2% | 1 | 10 |
| Pain | 36 | 3.2% | 0 | 15 |
| Arthralgia | 31 | 2.8% | 0 | 5 |
| Hypoaesthesia | 30 | 2.7% | 0 | 11 |
| Nausea | 27 | 2.4% | 0 | 8 |
| Sepsis | 24 | 2.2% | 3 | 21 |
| Pyrexia | 23 | 2.1% | 1 | 11 |
| Asthenia | 22 | 2.0% | 2 | 11 |
Other Indications for SATRALIZUMAB-MWGE
Neuromyelitis optica spectrum disorder (994)
Product used for unknown indication (84)
Myelitis (11)
Multiple sclerosis (7)
Myelin oligodendrocyte glycoprotein antibody-associated disease (5)
Other Drugs Used for Demyelination
RITUXIMAB (185)
METHYLPREDNISOLONE (52)
HUMAN IMMUNOGLOBULIN G (41)
TOCILIZUMAB (20)
TERIFLUNOMIDE (19)
OCRELIZUMAB (18)
PREDNISONE (16)
PREDNISOLONE (15)
DEXAMETHASONE (13)
CYCLOPHOSPHAMIDE (12)